Compare Charles River Laboratories Intl. Inc (CRL) vs Plug Power Inc (PLUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Plug Power Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $228.98 (market cap $11.14B), while Plug Power Inc trades at $2.29 (market cap $3.17B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 3.5× Plug Power Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Plug Power Inc nearer its low. Which is the better fit depends on your goals.
| CRL | PLUG | |
|---|---|---|
Market Cap | $11.14B | $3.17B |
Sector | Health | Industrials |
52-Week High | $233.60 | $4.14 |
52-Week Low | $145.57 | $1.40 |
Enterprise Value | $14.00B | $3.95B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Plug Power (PLUG) trades at $2.17, down 2.69% with a bearish technical signal. The company shows persistent financial challenges with negative profit margins (-227.13% net income margin) and cash flow issues, though recent asset sales aim to improve liquidity. Revenue grew to $710M in 2025 but remains unprofitable with significant losses. Analyst sentiment is mixed with 44.7% buy ratings and a $2.92 consensus target, while technical indicators show oversold conditions with RSI at 18.61.
The outlook remains challenging with profitability projected for 2028, but execution risks and continued cash burn pose significant hurdles. Near-term catalysts include $80M liquidity from recent asset sales and project milestones, though elevated short interest at 27.4% reflects skepticism. Investors face high volatility amid the company's turnaround efforts in the competitive hydrogen sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Plug Power Inc
Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets—including material handling, e-mobility, power generation, and industrial applications.
Read more on PLUG →
